Accutane Generic (Isotretinoin)

Medically reviewed by Dr. Sarah Mitchell, RPh, Clinical Pharmacist — Updated April 2026

What Is Accutane (Isotretinoin)? — Complete Mechanism of Action

Isotretinoin (13-cis-retinoic acid) is a synthetic retinoid — a structural isomer of all-trans-retinoic acid (tretinoin). While topical tretinoin acts primarily at the skin surface, oral isotretinoin distributes systemically and reaches all sebaceous glands throughout the body, producing a far more profound and lasting effect than any topical treatment.

Nuclear receptor mechanism — why isotretinoin works when nothing else does:

• RAR/RXR nuclear receptor binding: Isotretinoin binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXRs) in the nuclei of sebocytes (sebaceous gland cells) and keratinocytes. These receptor complexes act as ligand-dependent transcription factors — directly regulating the expression of hundreds of genes involved in sebaceous gland differentiation, cell proliferation, and inflammation
• Sebaceous gland involution — permanent structural change: Isotretinoin causes sebocyte apoptosis (programmed cell death) and inhibits sebocyte differentiation — leading to a dramatic, sustained reduction in sebaceous gland size (up to 90%) and sebum secretion (70–90%). This gland involution persists long after isotretinoin is discontinued — explaining the durable remission that distinguishes isotretinoin from all other acne treatments
• Normalisation of follicular keratinisation: Isotretinoin corrects the abnormal keratinocyte differentiation in the hair follicle that is the initiating event in acne — the formation of the microcomedo. By normalising the keratinisation process, isotretinoin prevents the follicular blockage from which all acne lesions originate
• Indirect elimination of C. acnes: With sebum reduced by 70–90%, the primary nutrient supply for Cutibacterium acnes bacteria is eliminated. C. acnes populations in follicles collapse as a consequence — without any direct antibiotic activity and without generating antibiotic resistance. This is why isotretinoin-treated skin remains clear years after treatment, while antibiotic-dependent regimens see acne return when antibiotics are stopped
• Anti-inflammatory effects: Isotretinoin reduces expression of Toll-like receptor 2 (TLR2) on keratinocytes, decreases inflammatory cytokine production (IL-1α, IL-8, TNF-α), and modulates neutrophil function — producing significant anti-inflammatory effects independent of its antisebaceous activity

Who Should Consider Isotretinoin in Canada

Canadian Dermatology Association (CDA) indications:

• Severe nodular or cystic acne — large (≥5mm), deep, painful acne lesions causing or at high risk of causing permanent scarring. This is the primary Health Canada-approved indication
• Moderate acne resistant to conventional therapy — acne that has not responded adequately to at minimum two 3-month courses of oral antibiotics (doxycycline or minocycline) combined with topical retinoids and benzoyl peroxide. "Adequate trial" means therapeutic doses maintained for the full duration — not short or interrupted courses
• Acne causing significant psychological distress — even if not objectively classified as severe; acne at any severity causing depression, social withdrawal, school/work avoidance, or significantly reduced quality of life. The Canadian Dermatology Association explicitly recognises psychological impact as an independent indication
• Gram-negative folliculitis — a form of folliculitis caused by gram-negative bacteria that develops as a complication of long-term antibiotic therapy for acne; responds well to isotretinoin
• Acne fulminans — acute, explosive onset of severe inflammatory acne with systemic features (fever, arthralgia, leukocytosis); requires isotretinoin (with initial systemic corticosteroids)
• Rapid acne relapse after antibiotics — for patients who clear on antibiotics but relapse rapidly upon stopping; isotretinoin offers the possibility of durable remission rather than indefinite antibiotic dependence

Why early isotretinoin is increasingly favoured by Canadian dermatologists: The traditional Canadian approach — cycling through multiple antibiotic courses before considering isotretinoin — is increasingly recognised as unnecessarily prolonging suffering and scarring. Every month of active nodular and cystic acne represents additional scarring risk. Canadian dermatologists now increasingly support earlier isotretinoin use for appropriate candidates rather than exhausting lengthy antibiotic courses that delay definitive treatment while allowing ongoing tissue destruction.

Isotretinoin vs Other Acne Treatments — The Canadian Comparison

Canadian Dosing Protocol

Starting dose: 0.5 mg/kg/day for the first 4 to 8 weeks — allows assessment of tolerability and minimises severity of the initial flare (see below). For a 70kg patient, this is 35mg daily — typically 20mg + 10mg capsules or one 40mg capsule with dose rounded to available strengths.

Maintenance dose: Increase to 1 mg/kg/day after 4 to 8 weeks if tolerated. The maximum generally used dose in Canada is 1 mg/kg/day — higher doses (up to 2 mg/kg/day) are occasionally used by specialist dermatologists in specific circumstances but are not standard. A 70kg patient would typically be on 70mg/day during maintenance — rounded to 40mg + 30mg or 60mg + 10mg depending on available strengths.

Cumulative dose target — the most important dosing concept: The key determinant of durable remission is the total cumulative dose received over the course — not daily dose or duration alone. The target cumulative dose in Canada is 120 to 150 mg/kg total body weight. For a 70kg patient, this means 8,400 to 10,500mg total isotretinoin over the course. Achieving this cumulative target is strongly associated with durable remission — patients who complete sub-therapeutic cumulative doses have significantly higher relapse rates. This is why rushing through a short course at very high doses, or stopping early because skin has cleared, increases relapse risk.

Course duration: Most Canadian patients complete isotretinoin in 4 to 6 months at standard doses (0.5–1 mg/kg/day). Shorter courses may not achieve the target cumulative dose. Longer courses at lower doses (micro-dosing) are used by some Canadian dermatologists for patients who cannot tolerate standard doses.

Critical — take with food: Isotretinoin is highly lipophilic. Taking with a full meal (particularly a fat-containing meal) increases absorption by approximately 2-fold compared to fasting. Always take isotretinoin with the largest meal of the day — typically dinner. Swallow capsules whole with a full glass of water.

Missed dose: Take the missed dose as soon as remembered, unless it is almost time for the next dose. Do not double up. The next dose should be taken at the regular time.

The Accutane "Purge" / Initial Flare — What Canadian Patients Must Know

The "Accutane purge" or "initial flare" is one of the most frequently searched topics about isotretinoin in Canada — and one of the most common reasons patients prematurely stop treatment.

What it is: Approximately 5–10% of isotretinoin patients experience a transient worsening of acne in the first 2 to 8 weeks of treatment, before improvement begins. Existing acne lesions may appear more inflamed, and new lesions may emerge from follicles that were already in the process of forming but not yet visible.

Why it happens: The initial surge in retinoid activity causes rapid mobilisation of retained sebum from sebaceous glands, rapid keratinocyte turnover expelling impacted follicular material, and a brief pro-inflammatory phase before anti-inflammatory effects dominate. This is a consequence of the drug working — not a sign of treatment failure.

Who is most at risk of severe initial flare: Patients with extensive comedonal or cystic acne, young male patients with particularly large sebaceous glands, and patients started on higher initial doses. Patients with very extensive or severe acne are sometimes pre-treated with oral prednisone (30–40mg/day for 4–6 weeks) before isotretinoin to prevent acne fulminans-type flare — a dermatologist decision.

How to minimise the purge:

• Start at a lower dose (0.5 mg/kg/day or even lower) for the first 4–8 weeks — allow gradual sebaceous gland adaptation
• Do not start at the maximum dose immediately
• Continue topical treatments (gentle, non-comedogenic moisturiser, sunscreen) — avoid anything potentially irritating
• Discuss with your dermatologist whether a short oral corticosteroid course before isotretinoin is appropriate if you have very extensive acne
• Understand that flare, if it occurs, is temporary — most patients who experience it see it resolve within 4–8 weeks, after which significant skin improvement begins

Health Canada Requirements — Isotretinoin Teratogenicity Awareness Program

Isotretinoin is a human teratogen — it causes characteristic, severe birth defects in virtually every fetus exposed during pregnancy. These include craniofacial malformations (microcephaly, microtia/anotia, hypertelorism), cardiac defects (conotruncal malformations), thymus and parathyroid gland anomalies, CNS malformations, and extremity defects. Even a single dose taken during pregnancy can cause these defects — there is no safe dose of isotretinoin in pregnancy.

What Health Canada requires for Canadian women on isotretinoin:

• Two simultaneous forms of effective contraception beginning one full month before starting isotretinoin, continuing throughout treatment, and for one full month after the last dose. "Two forms" means a primary method (hormonal contraceptive — pill, patch, ring, injection, IUD with hormones) PLUS a barrier method (condom with spermicide), OR two barrier methods if hormonal contraception is contraindicated. Abstinence is acceptable as the sole method only if it is the patient's reliable choice
• Negative pregnancy test before each monthly prescription — urine or serum hCG. This must be performed at the prescribing physician's office or a certified laboratory. Results must be documented before the next 30-day supply is dispensed
• Acknowledgement of teratogenicity risks in writing — patients sign informed consent documentation before starting isotretinoin
• Regular follow-up visits — monthly for the duration of treatment; this is not optional as it coincides with pregnancy test, blood work review, and dispensing of the next 30-day supply

For male patients: While isotretinoin does not cause birth defects through semen exposure (sperm are not teratogenically affected at therapeutic doses), male patients should still use contraception as a general precaution and should not donate blood during treatment or for one month after completing the course (donated blood could potentially be given to a pregnant woman).

If pregnancy occurs during isotretinoin treatment: Stop isotretinoin immediately. Contact your physician or the nearest prenatal care centre. Do not attempt to manage this situation independently. Pregnancy during isotretinoin treatment is a serious medical situation requiring immediate specialist guidance.

Required Laboratory Monitoring During Isotretinoin Treatment in Canada

Health Canada and Canadian dermatology guidelines require laboratory monitoring before and during isotretinoin therapy. All tests below are typically ordered by your prescribing dermatologist or physician:

Before starting isotretinoin (baseline):

• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) — isotretinoin frequently elevates triglycerides; very high triglycerides (>800 mg/dL) contraindicate treatment due to pancreatitis risk
• Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) — isotretinoin is hepatically metabolised and can elevate transaminases
• Complete blood count (CBC) — baseline haematological status
• Pregnancy test (urine hCG) — mandatory for all women of childbearing potential, performed at the prescribing physician's office

Monthly monitoring during treatment:

• Fasting lipid panel — triglycerides must be checked monthly; if >500 mg/dL, dose reduction or temporary cessation may be needed; if >800 mg/dL, treatment stopped
• Liver function tests — if ALT/AST exceed 3× upper limit of normal, consider dose reduction or temporary cessation
• Pregnancy test — mandatory before each monthly supply is dispensed for women of childbearing potential
• CBC — monthly in patients with abnormal baseline; every 1–3 months otherwise

Canadian Medicare/provincial coverage: In most Canadian provinces, the blood tests required for isotretinoin monitoring are covered under provincial health insurance (OHIP in Ontario, RAMQ in Quebec, MSP in British Columbia, AHCIP in Alberta, etc.) when ordered by a physician for the documented indication. Confirm coverage with your provincial health plan. The cost of physician and dermatology visits for monitoring is covered by provincial insurance for Canadian residents with valid health cards.

Side Effects — Complete Canadian Guide

Very common — affecting virtually all patients (>80%):

• Mucocutaneous dryness — the defining side effect of isotretinoin:
  • Cheilitis (dry, chapped, peeling lips) — the most universal side effect; occurs in virtually 100% of patients. Daily application of a thick, fragrance-free lip balm (Vaseline, Aquaphor, CeraVe Healing Ointment) is essential. Some Canadian dermatologists recommend applying lip balm before bed and keeping it at bedside
  • Dry, sensitive facial skin — switch to a gentle, non-comedogenic, fragrance-free moisturiser (CeraVe Moisturising Cream, Vanicream, La Roche-Posay Toleriane). Apply morning and night. Avoid foaming or drying cleansers — use micellar water or a cream cleanser
  • Dry nasal passages and nosebleeds — saline nasal spray (Hydrasense, ACTS) 2–3 times daily; Polysporin or petroleum jelly applied to nasal septum at night reduces epistaxis
  • Dry eyes — use preservative-free artificial tears (Systane Ultra, Refresh Tears) as needed; avoid contact lens use during isotretinoin treatment if possible; contact lens intolerance is very common on isotretinoin
• Photosensitivity — skin becomes significantly more sensitive to UV radiation on isotretinoin. Always apply broad-spectrum SPF 30+ sunscreen (mineral-based preferred — zinc oxide, titanium dioxide — as chemical UV filters may irritate isotretinoin-sensitised skin) every morning without exception. Avoid prolonged sun exposure and tanning beds throughout treatment and for several months after
• Initial flare — see dedicated section above

Common — affecting 10–50% of patients:

• Musculoskeletal pain — myalgia (muscle aches), arthralgia (joint pain), back pain particularly in young athletes. Usually mild and manageable with acetaminophen (Tylenol). NSAIDs (ibuprofen, naproxen) should be used with caution as they can interact with isotretinoin. High-intensity athletic training (contact sports, heavy weightlifting) may need modification during treatment. Pain usually resolves completely after treatment ends
• Headache — usually mild; persistent or severe headache (especially with visual disturbances) requires urgent medical attention to rule out pseudotumour cerebri (see below)
• Elevated triglycerides — monitored monthly; dietary modification (reduce refined carbohydrates, sugars, alcohol) and occasionally omega-3 supplementation can help. Dose reduction may be needed if triglycerides are very elevated
• Elevated liver enzymes (transaminases) — usually mild and reversible; monitored monthly

Uncommon but important — requiring medical attention:

• Pseudotumour cerebri (intracranial hypertension): Presents as persistent severe headache, visual disturbances (blurring, double vision), nausea, and vomiting. Rare but serious — requires urgent ophthalmological assessment. Risk increases if tetracyclines (doxycycline, minocycline) are taken concurrently with isotretinoin — this combination is absolutely contraindicated
• Visual disturbances: Decreased night vision (night blindness) — report to prescribing physician; may persist after treatment. Corneal opacities — rare. Serious vision changes require stopping isotretinoin and urgent ophthalmology referral
• Inflammatory bowel disease (IBD) — controversial Canadian context: There is a longstanding and debated question about whether isotretinoin is associated with an increased risk of Crohn's disease and ulcerative colitis. Current evidence does not establish a causal relationship — isotretinoin-treated patients with severe acne may have confounding factors. However, Health Canada advises reporting new or worsening GI symptoms (severe diarrhoea, abdominal pain, rectal bleeding) during or after isotretinoin. Canadian patients with a personal or strong family history of IBD should discuss this specific concern with their dermatologist before starting isotretinoin
• Skeletal effects in adolescents: Premature epiphyseal closure (growth plate closure) has been reported with prolonged use in growing adolescents. This is of concern only in patients who have not completed skeletal growth. Canadian dermatologists assess bone age and growth status in very young adolescents before prescribing

Psychiatric effects — Health Canada Black Box Warning:

Health Canada requires isotretinoin to carry a warning about psychiatric adverse effects. Reports of depression, suicidal ideation, suicide attempts, and completed suicides in isotretinoin-treated patients exist in the post-marketing literature. However, the causal relationship remains scientifically controversial — multiple well-designed studies, including a large Swedish registry study of over 5,700 isotretinoin-treated patients, have not found an increased risk of depression or suicidality compared to untreated acne patients; some studies show improved mental health after treatment as acne improves.

The current understanding in Canadian dermatology is that: (1) isotretinoin may rarely cause or worsen depression in susceptible individuals; (2) severe acne itself is a significant cause of depression and poor mental health; (3) baseline depression screening before starting isotretinoin is important; (4) patients and families should be counselled to report any mood changes, feelings of depression, unusual behaviours, or thoughts of self-harm immediately to the prescribing physician.

If you experience mood changes, depression, thoughts of self-harm, or any psychiatric symptoms during isotretinoin treatment — contact your physician immediately. In an emergency, call 9-8-8 (Canada Suicide Crisis Helpline) or go to the nearest emergency department. Do not stop isotretinoin abruptly without medical guidance.

Absolute Contraindications

• Pregnancy — Category X, absolute contraindication. Even a single dose can cause severe, characteristic birth defects. Two simultaneous contraceptive methods mandatory (see Health Canada requirements section above)
• Breastfeeding — isotretinoin passes into breast milk; contraindicated during breastfeeding
• Known hypersensitivity to isotretinoin, vitamin A, or any capsule excipient (includes soybean oil, parabens, EDTA — review product monograph for complete excipient list)
• Severe hepatic impairment — isotretinoin is extensively hepatically metabolised; contraindicated in severe liver disease
• Severe hyperlipidaemia (triglycerides >800 mg/dL, uncontrolled) — pancreatitis risk
• Concurrent tetracyclines (doxycycline, minocycline, tetracycline) — additive risk of pseudotumour cerebri (intracranial hypertension). This combination is absolutely contraindicated. Tetracyclines must be stopped before isotretinoin is started
• Concurrent Vitamin A supplements — additive hypervitaminosis A toxicity risk. Multivitamins containing Vitamin A should be avoided; Vitamin A supplements are contraindicated

Key Drug Interactions

• Tetracycline antibiotics (doxycycline, minocycline, tetracycline) — absolute contraindication. Additive risk of pseudotumour cerebri (raised intracranial pressure). Stop tetracyclines before starting isotretinoin — allow at least 1–2 weeks washout
• Vitamin A and retinoid supplements — contraindicated. Additive hypervitaminosis A toxicity including hepatotoxicity, intracranial hypertension, bone changes
• Methotrexate — combined hepatotoxicity risk; combination is generally avoided
• Phenytoin — isotretinoin may increase phenytoin serum levels; monitoring required in epileptic patients
• Micro-dosed progesterone-only oral contraceptives ("mini-pill") — theoretical concern that high-dose isotretinoin may reduce efficacy of very low-dose progestins; an additional barrier method is advisable if mini-pill is the chosen contraception. Combined hormonal contraceptives (estrogen + progestin) are not affected
• St. John's Wort — may reduce hormonal contraceptive efficacy; avoid during isotretinoin treatment in women relying on hormonal contraception

Delivery to All Canadian Provinces and Territories

drugs-canada.com ships Accutane Generic discreetly to all Canadian provinces and territories. Standard delivery: 4–9 business days.

Ontario (Toronto, Ottawa, Hamilton, London, Brampton, Mississauga, Kitchener-Waterloo) — Quebec (Montreal, Quebec City, Laval, Gatineau, Sherbrooke) — British Columbia (Vancouver, Surrey, Burnaby, Victoria, Kelowna, Abbotsford) — Alberta (Calgary, Edmonton, Red Deer, Lethbridge) — Manitoba (Winnipeg, Brandon) — Saskatchewan (Saskatoon, Regina) — Nova Scotia (Halifax, Sydney) — New Brunswick (Moncton, Saint John, Fredericton) — Newfoundland and Labrador (St. John's, Corner Brook) — Prince Edward Island (Charlottetown) — Northwest Territories (Yellowknife) — Yukon (Whitehorse) — Nunavut (Iqaluit).

All orders are dispatched in plain, unmarked packaging with no reference to the contents or sender. Every order includes a tracking number.

Frequently Asked Questions — Accutane (Isotretinoin) in Canada

How long does one course of Accutane take in Canada? A standard isotretinoin course in Canada typically lasts 4 to 6 months at doses of 0.5 to 1 mg/kg/day. The critical parameter is achieving the target cumulative dose of 120 to 150 mg/kg of total body weight — this cumulative dose threshold is more predictive of durable remission than duration alone. A 70kg patient needs 8,400 to 10,500mg total isotretinoin. Stopping early because your skin has cleared (before reaching the cumulative dose target) significantly increases the risk of relapse and may require a second course.

What is the Accutane purge and how long does it last? The "Accutane purge" (initial flare) is a temporary worsening of acne that affects approximately 5–10% of patients in the first 2 to 8 weeks of treatment. It occurs because retinoid activity mobilises retained sebum from follicles and accelerates cell turnover, temporarily making existing lesions more visible before they resolve. It is a sign that the medication is working — not a sign of failure. Starting at a low dose (0.5 mg/kg/day) rather than the maximum dose reduces severity. The flare resolves on its own within 4 to 8 weeks, after which consistent improvement begins.

Can I drink alcohol while on isotretinoin? Alcohol should be significantly restricted or eliminated during isotretinoin treatment. Both isotretinoin and alcohol are metabolised by the liver — concurrent use increases hepatotoxicity risk and can substantially elevate triglycerides (which are already often elevated by isotretinoin alone). Your monthly liver function tests will detect any problem, but preventing liver stress during treatment is preferable. Occasional very modest consumption (1 drink on a rare social occasion) is generally tolerated by most patients, but regular drinking is incompatible with safe isotretinoin treatment.

Will isotretinoin cause depression? This is one of the most frequently asked questions about isotretinoin in Canada. Health Canada requires a psychiatric warning on isotretinoin due to post-marketing reports of depression and suicidality. However, large pharmacoepidemiological studies have not confirmed a causal relationship — severe acne itself is a major cause of depression and anxiety, and multiple studies show overall mental health improvement as acne resolves on isotretinoin. The current Canadian dermatology position is: (1) baseline mood should be assessed before starting; (2) patients and families should be counselled to report any mood changes to their physician immediately; (3) isotretinoin should be used with increased caution and closer psychiatric monitoring in patients with pre-existing depression. If you experience mood changes on isotretinoin — contact your physician immediately rather than stopping abruptly without guidance.

Can I take isotretinoin if I have inflammatory bowel disease (IBD) in my family? A personal or family history of IBD (Crohn's disease or ulcerative colitis) is a relative contraindication that should be discussed openly with your Canadian dermatologist before starting isotretinoin. The evidence for isotretinoin causing IBD is controversial and inconclusive, but a cautious approach in patients with strong IBD family history is reasonable. Your dermatologist can help weigh the acne treatment benefit against this theoretical risk for your specific situation.

How long does delivery to Canada take? Standard delivery to all Canadian provinces and territories takes 4 to 9 business days. All orders arrive in plain, unmarked packaging with no reference to the contents or sender. Every order includes a tracking number.

All information on this page is for general informational purposes only and does not constitute medical advice. Isotretinoin is a Schedule F prescription medicine in Canada requiring a valid prescription from a licensed Canadian physician or dermatologist. It is absolutely contraindicated in pregnancy. Always consult a qualified Canadian healthcare provider before starting isotretinoin treatment. If you experience suicidal thoughts or are in a mental health crisis, call 9-8-8 (Canada Suicide Crisis Helpline, available 24/7) or go to the nearest emergency department.